COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Transcranial Magnetic Stimulation for the Treatment of Auditory Hallucinations in Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01595503
Recruitment Status : Completed
First Posted : May 10, 2012
Last Update Posted : July 16, 2013
Information provided by (Responsible Party):
Stephan Taylor, University of Michigan

Brief Summary:
Repetitive transcranial magnetic stimulation (rTMS) is a new noninvasive therapy that uses magnetic energy applied to the scalp to modulate activity in the underlying regions of the brain. In this study we will examine the efficacy of treating auditory hallucinations in schizophrenia with rTMS, comparing two methods to target stimulation to a language processing region of the brain. One method targets the stimulation site using scalp landmarks, while the other uses functional magnetic resonance imaging (fMRI) combined with a language task.

Condition or disease Intervention/treatment Phase
Schizophrenia Procedure: rTMS with fMRI-based targeting Procedure: rTMS with landmark-based targeting Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Functional Targeting of Transcranial Magnetic Stimulation for the Treatment of Refractory Auditory Hallucinations in Schizophrenia
Study Start Date : May 2011
Actual Primary Completion Date : August 2012
Actual Study Completion Date : August 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Experimental: fMRI-based targeting Procedure: rTMS with fMRI-based targeting
Inhibitory (low frequency) 1-Hz rTMS will be applied to the secondary auditory cortex during 10 daily 20-minute treatment sessions. An fMRI scan combined with a language task will be used to localize the secondary auditory cortex, followed by neuronavigation to identify the scalp location overlying the targeted cortex.

Active Comparator: landmark-based targeting Procedure: rTMS with landmark-based targeting
Inhibitory (low frequency) 1-Hz rTMS will be applied over the left temporoparietal cortex (TPC) during 10 daily 20-minute treatment sessions, with the stimulating coil located midway between the left temporal (T3) and parietal (P3) scalp landmarks, using the International 10-20 system for EEG.

Primary Outcome Measures :
  1. Change in severity of auditory hallucinations [ Time Frame: Baseline, one week, two weeks, 1 month, 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Provide signed and dated informed consent form
  • Male or female, aged 18 to 60
  • Willing to comply with all study procedures and be available for the duration of the study
  • Primary diagnosis of schizophrenia or schizoaffective disorder according to DSM-IV (29)
  • Currently reporting AHs, rated a minimum of 4 (moderate) on the auditory hallucination item of the Brief Psychiatric Rating Scale (BPRS; 27), and AH will be present daily
  • AHs must have failed to resolve after a minimum of two adequate trials (doses within standard therapeutic range for a minimum of 8 weeks each) of psychotropic medication including at least one atypical antipsychotic medication; documented trials of antipsychotic medication limited by intolerable side effects, e. g. extra-pyramidal symptoms, tardive dyskinesia, weight gain, neuroleptic-induced dysphoria, will also be considered as equivalent to adequate trials.
  • Weight and girth compatible with the bore of the MRI scanner; generally men over 6 feet tall < 250 lbs, men under 6 feet tall < 220 lbs, women over 5'11" tall < 220 lbs, or women under 5'10" tall < 200 lbs

Exclusion Criteria:

  • Substance abuse or dependence in the past 1 month
  • Current or past history of serious medical or neurological illness that could compromise brain function or present an increased risk of seizure, e. g. conditions that may significantly alter electrolyte balance, stroke, epilepsy, any history of seizure;
  • Pregnant or trying to become pregnant;
  • Inability to tolerate small, enclosed spaces without anxiety;
  • Metals, implants or metallic substances within or on the body that might cause adverse effects to the subject in a strong magnetic field, or interfere with image acquisition, e. g. aneurysm clips, retained particles, neurostimulators, foil-backed transdermal patches;
  • Facial tattoos with metallic ink
  • Inability to follow study protocol
  • Change in antipsychotic therapy in previous 2 weeks
  • Currently under an alternative treatment order
  • Unstable symptoms which could, in the judgment of the study team, exhibit symptomatic worsening over the course of the protocol
  • Current treatment with another investigational drug or other intervention
  • Anything that, in the opinion of the investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study;
  • No quantifiable motor threshold such that TMS dosage cannot be accurately determined

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01595503

Layout table for location information
United States, Michigan
University of Michigan Department of Psychiatry Depression Center
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
University of Michigan
Layout table for investigator information
Principal Investigator: Stephan F Taylor, M.D. University of Michigan
Layout table for additonal information
Responsible Party: Stephan Taylor, Professor of Psychiatry, University of Michigan Identifier: NCT01595503    
Other Study ID Numbers: HUM00046254
First Posted: May 10, 2012    Key Record Dates
Last Update Posted: July 16, 2013
Last Verified: July 2013
Keywords provided by Stephan Taylor, University of Michigan:
Schizophrenia, auditory hallucination
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Perceptual Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases